Tripep’s rights offering

The Board of Directors of Tripep has on the 3 of November 2008, based on the authorization by the AGM of 9 April 2008, resolved to carry out a rights issue with a maximum of 9,786,224 shares. The rights issue has been fully subscribed and consequently raised approx. 4.9 MSEK before transaction costs. 57 % has been subscribed for using first rights. 43 % has been subscribed for without rights.




For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, Mobile phone: +46 70 466 31 63,
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se




About Tripep
Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.